PSA tests are wrong more often than most people expect. When a PSA result comes back elevated (above 4.0 ng/mL), only about 22 to 27% of men who go on to have a biopsy actually have prostate cancer. That means roughly three out of four elevated results in the most common range turn out to be false alarms. On the other side, the test misses a small but real number of cancers in men whose PSA looks normal.
How Often Elevated Results Are False Alarms
The PSA range that causes the most confusion is between 4.0 and 10.0 ng/mL, sometimes called the “gray zone.” In this range, biopsies confirm cancer only 22 to 27% of the time. The remaining 73 to 78% of men who undergo a biopsy based on these numbers have benign tissue. When PSA rises above 10.0 ng/mL, the odds shift significantly: about 67% of biopsies at that level do find cancer. But for the millions of men whose PSA falls in the gray zone, the false positive rate is high enough that it drives a large number of unnecessary biopsies, anxiety, and follow-up procedures.
How Often the Test Misses Real Cancers
False negatives are less common but still important. A large screening study found that among men whose PSA was below 3.0 ng/mL (well within the “normal” range), about 0.5% were later diagnosed with clinically significant prostate cancer within four years. The overall false negative rate for any prostate cancer, including slow-growing types, was 2.6%. So a normal PSA result is reassuring for most men, but it does not guarantee the absence of cancer.
Why the Test Gets It Wrong
PSA is not a cancer-specific marker. It measures a protein produced by all prostate tissue, not just cancerous cells. Several common, noncancerous conditions raise PSA levels and trigger false positives:
- Benign prostatic hyperplasia (BPH): An enlarged prostate produces more PSA simply because there is more prostate tissue. BPH becomes increasingly common after age 50.
- Prostatitis: Infection or inflammation of the prostate can spike PSA dramatically, sometimes into ranges that mimic aggressive cancer.
- Urinary tract infections: These can temporarily elevate PSA, particularly in men.
- Recent prostate stimulation: A digital rectal exam, prostate biopsy, or even vigorous cycling can bump PSA levels for days to weeks.
- Ejaculation: Sexual activity shortly before a blood draw can cause a temporary increase.
Because so many everyday factors influence the number, a single elevated reading is a poor basis for major decisions. Repeating the test after a few weeks, avoiding the triggers listed above, and looking at additional markers all help clarify whether an elevated result is meaningful.
Age Changes What “Normal” Means
PSA naturally rises as men get older, which means a fixed cutoff of 4.0 ng/mL overstates risk in younger men and understates it in older men. A 2025 analysis of nearly 14,000 men found that the 95th percentile PSA value (meaning only 5% of healthy men exceed it) increases substantially by decade: 1.81 ng/mL for men aged 40 to 49, 3.23 ng/mL for ages 50 to 59, 4.15 ng/mL for ages 60 to 69, and 5.53 ng/mL for ages 70 to 79.
This matters for accuracy. A 45-year-old with a PSA of 2.5 may warrant closer attention even though he’s below the traditional 4.0 cutoff, while a 72-year-old at 4.5 might be perfectly normal for his age. Age-adjusted reference ranges reduce both false positives in older men and false negatives in younger men.
Medications That Distort Results
If you take finasteride or dutasteride (commonly prescribed for hair loss or enlarged prostate), your PSA results will look artificially low. Finasteride cuts PSA levels by roughly 50% within the first year of use. Over longer periods, the suppression increases: after seven years, PSA values need to be multiplied by about 2.5 to approximate what the true reading would be without the medication. If your doctor isn’t aware you’re taking one of these drugs, a cancer could be hiding behind a deceptively normal-looking number.
Tools That Improve Accuracy
Because a single PSA number is so unreliable on its own, doctors use several strategies to separate true positives from false ones before recommending a biopsy.
PSA Velocity
Rather than relying on one reading, tracking PSA over time reveals how quickly the number is climbing. A rise of 0.75 ng/mL or more per year has historically been used to distinguish prostate cancer from benign enlargement. Rapid increases are more suspicious than a single high value that stays stable.
PSA Density
This compares your PSA level to the size of your prostate, measured by ultrasound or MRI. A large prostate naturally produces more PSA, so dividing the PSA value by prostate volume helps distinguish men with big but healthy prostates from those with smaller glands harboring cancer.
MRI Before Biopsy
Multiparametric MRI has become an increasingly common step between an elevated PSA and a biopsy. The landmark PROMIS trial found that using MRI to triage men with elevated PSA allowed 27% of patients to avoid a biopsy entirely, while also reducing the detection of clinically insignificant cancers by 5%. In other words, MRI helps filter out the false alarms and focus biopsies on men who are more likely to have meaningful disease. It costs 10 to 20 times more than a PSA blood test, so it is typically reserved for men whose PSA results are already concerning rather than used as a first-line screen.
Screening Frequency and Overdiagnosis
How often you get tested also affects how often the test will be “wrong” in a practical sense. Annual screening catches more cancers, but it also catches more slow-growing tumors that would never cause symptoms during a man’s lifetime. Detecting and treating these indolent cancers counts as overdiagnosis, a form of false alarm that can lead to unnecessary surgery or radiation with real side effects.
The U.S. Preventive Services Task Force notes that screening every two to four years instead of annually provides a good balance: it maintains most of the life-saving benefit while substantially reducing overdiagnosis. The American Urological Association similarly recommends intervals of two years or more for men aged 55 to 69. For men 70 and older, the Task Force recommends against routine PSA screening altogether, largely because the risk of overdiagnosis outweighs the benefit at that age.
Extending the interval between tests, using higher PSA thresholds before recommending a biopsy, and incorporating MRI all work together to reduce the chance that a screening program does more harm than good. A single PSA number, taken in isolation, is a blunt instrument. Combined with age-adjusted ranges, repeat measurements over time, and imaging when needed, the overall accuracy improves considerably.